Wilmington Savings Fund Society FSB Acquires New Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $89,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Dynavax Technologies by 1.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 1,172 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Dynavax Technologies by 9.1% during the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after acquiring an additional 1,484 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. Finally, Louisiana State Employees Retirement System grew its stake in Dynavax Technologies by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after purchasing an additional 1,900 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Trading Down 0.3 %

Shares of NASDAQ:DVAX opened at $12.72 on Friday. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.01. The company’s 50 day moving average is $12.24 and its two-hundred day moving average is $11.52. The company has a market cap of $1.67 billion, a PE ratio of 97.85 and a beta of 1.33. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.